Physician profile
Sifredo Acaron
NPI 1659481323
$2,499.26
in general payments reported to CMS, 2019-2025
16 companies · $473 in 2025
The $473 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $332 · 2021: $235 · 2022: $324 · 2023: $488 · 2024: $448 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745 · Education: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.24 |
| Education | $664.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $761.81 | 2019-2025 | Opdivo, Pomalyst, Reblozyl |
| Janssen Biotech, INC. | $546.96 | 2020-2025 | Erleada, Darzalex |
| Janssen Pharmaceuticals, INC | $345.81 | 2019-2025 | Xarelto, Darzalex |
| Abbvie INC. | $220.51 | 2021-2025 | Avycaz |
| Eli Lilly Export S.A. Puerto Rico Branch | $188.10 | 2023 | |
| Incyte Corporation | $93.95 | 2024 | |
| Boston Scientific Corporation | $71.06 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.28 | 2022 | |
| Celgene Corporation | $47.52 | 2021 | |
| Kite Pharma, INC. | $41.76 | 2019 | |
| Pfizer INC. | $27.37 | 2019-2021 | |
| Biotronik INC. | $24.48 | 2019 | |
| Merck Sharp & Dohme LLC | $23.13 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.42 | 2022 | |
| Pharmaand Gmbh | $14.05 | 2025 | Rubraca |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $14.05 | 2025 | Rubraca, Eligard |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sifredo Acaron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.